Skip to Main Content
Back to News

Insider Purchase: Director at $IMRX Buys 3,000 Shares

Automated

DIANA HAUSMAN, a director at $IMRX, bought 3,000 shares of the company on 07-02-2025 for an estimated $10,873. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately inf%. Following this trade, they now own 3,000 shares of this class of $IMRX stock.

$IMRX Insider Trading Activity

$IMRX insiders have traded $IMRX stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:

  • THOMAS J. SCHALL has made 2 purchases buying 49,985 shares for an estimated $124,065 and 0 sales.
  • BENJAMIN J. ZESKIND (PRESIDENT AND CEO) has made 3 purchases buying 31,000 shares for an estimated $85,023 and 0 sales.
  • PETER FEINBERG purchased 25,000 shares for an estimated $63,187
  • BRETT MATTHEW HALL (CHIEF SCIENTIFIC OFFICER) has made 2 purchases buying 13,422 shares for an estimated $34,616 and 0 sales.
  • DIANA HAUSMAN has made 2 purchases buying 5,500 shares for an estimated $19,862 and 0 sales.
  • HAROLD EUGENE BRAKEWOOD (Chief Business Officer) purchased 1,900 shares for an estimated $4,804
  • LEAH R NEUFELD (CHIEF PEOPLE OFFICER) purchased 700 shares for an estimated $2,498

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IMRX Hedge Fund Activity

We have seen 14 institutional investors add shares of $IMRX stock to their portfolio, and 20 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$IMRX Analyst Ratings

Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Oppenheimer issued a "Outperform" rating on 05/07/2025

To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles